In this article, we will take a look at the 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market.
Novo Nordisk A/S (NYSE: NVO) helped transform obesity treatment from a relatively overlooked pharmaceutical category into one of Wall Street’s biggest healthcare stories. The success of GLP-1 weight-loss drugs proved that effective obesity medicines could generate blockbuster sales, attract millions of patients and reshape how doctors treat metabolic disease.
The opportunity is enormous. Obesity affects hundreds of millions of people worldwide and is associated with type 2 diabetes, cardiovascular disease, fatty-liver disease, sleep apnea and other serious health conditions. Yet only a small percentage of eligible patients currently receives modern prescription weight-loss treatments. That gap explains why analysts believe the global weight-loss drug market could eventually exceed $100 billion in annual sales.
The Next Winners May Offer More Than Weight Loss
The next phase of the obesity drug boom will not be based solely on which treatment produces the highest percentage of weight loss. Drugmakers are now developing oral GLP-1 pills, monthly injections, dual- and triple-hormone therapies, amylin-based medicines and treatments designed to preserve muscle while patients lose fat.
Here is an important piece of trivia: weight loss does not come entirely from body fat. Patients may also lose lean tissue, including muscle, which has pushed biotechnology companies to develop complementary treatments that improve the quality of weight loss. Others are working on easier dosing, fewer gastrointestinal side effects and medicines that may also improve liver, heart and metabolic health.
Oral obesity treatments could become especially disruptive. Many patients dislike needles, while pills may be easier to manufacture, distribute and use. A successful weight-loss pill would not necessarily need to outperform every injectable treatment. Convenience alone could allow it to capture a meaningful portion of the growing obesity treatment market.
Why Biotech Stocks Are Entering the Spotlight
Novo Nordisk A/S (NYSE: NVO) remains the company framing this story, but it is not included in the top 10 ranking. Instead, the countdown focuses on biotechnology stocks attempting to benefit from the market Novo Nordisk helped create.
Some of these companies are developing direct competitors to existing GLP-1 drugs. Others are pursuing different mechanisms, longer-lasting treatments or therapies that could eventually be prescribed alongside popular weight-loss medicines. Their success could lead to major commercial partnerships, acquisition interest or sharp valuation increases.
The risks are equally significant. Obesity drug trials are expensive, clinical results can disappoint and smaller biotechnology companies may need additional financing before reaching commercialization. Investors searching for the best biotech stocks to buy now should therefore examine clinical progress, cash reserves, safety data, competitive advantages and upcoming catalysts—not just ambitious weight-loss claims.
The following countdown identifies 10 biotechnology stocks positioned to participate in the next stage of the $100 billion weight-loss drug market, beginning with number 10 and moving toward the company offering the strongest combination of scientific promise, market opportunity and investment potential.
CHECK THIS OUT: Top 10 AI-Powered Healthcare Stocks That Can Make You Rich and Top 10 Healthcare Stocks That Could Turn a $1000 Investment Into Something Bigger.
Our Methodology
In order to arrive to our list of the 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market, we examined the trending biotech stocks and based our ranking on each company’s clinical progress, treatment differentiation, market opportunity, financial position, upcoming catalysts, partnership potential and overall risk-reward profile within the rapidly growing obesity and metabolic-disease market.
10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market
10. Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) takes the number 10 position because it offers one of the more unusual approaches to obesity treatment. Its experimental oral drug, CRB-913, is not another GLP-1 medicine. It is a highly peripherally restricted cannabinoid type-1 receptor inverse agonist designed to produce the metabolic benefits associated with blocking CB1 while limiting the drug’s entry into the brain. That distinction matters because an earlier CB1 treatment, rimonabant, was abandoned after serious concerns involving psychiatric side effects. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is attempting to revive the biological target with a drug engineered to act mainly outside the central nervous system.
The early clinical evidence remains limited, but it has been strong enough to keep investors interested. In a Phase 1a study, CRB-913 produced placebo-adjusted mean weight loss of approximately 2.9% after only 14 days in a small cohort of people with obesity. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported no concerning findings in daily assessments for suicidal ideation, depression or anxiety across the evaluated participants. The company subsequently advanced the drug into the 240-patient CANYON-1 Phase 1b trial and said in April 2026 that it expected to complete the 16-week dose-finding study during the summer.
Chief Executive Officer Yuval Cohen described CRB-913 as a potential “orthogonal drug class” within the obesity-treatment landscape, meaning it could eventually be used independently or alongside established incretin therapies. That is the attraction—and the danger—of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP). Strong Phase 1b results could quickly elevate the company into serious partnership or acquisition discussions. Weak efficacy or any neuropsychiatric signal could severely damage the program. Among the obesity biotech stocks in this ranking, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is one of the most speculative, but its different mechanism could become valuable if the market begins demanding alternatives to GLP-1 medicines.
Click next to see the following stock...
